Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536272 | 0.87 | TPMT (0.41) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL23395827 | 0.87 | MEN1 (0.50) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL19137597 | 0.85 | GPR139 (0.42) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL24162333 | 0.85 | MAPT (0.40) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL15587366 | 0.85 | CES2 (0.41) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL11382828 | 0.84 | MAPT (0.50) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL23455654 | 0.80 | RAB9A (0.44) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL27856961 | 0.80 | NOTUM (0.63) | PPARAPPARGGSK3BALDH1A1 | |
| SCHEMBL31123489 | 0.80 | RAB9A (0.44) | MAPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL5254952 | 0.80 | GSK3B (0.41) | MAPTL3MBTL1KMT2AMEN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| CN-105473569-A | Compound, material for organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO | 2016-04-06 | — | — | CN | disclosed |
| CN-100512582-C | Light emitting system, light emitting method and chemical substance for light emission | HITACHI CHEMICAL CO LTD (JP) | 2009-07-08 | — | — | CN | disclosed |
| EP-1463741-A4 | COMPOUNDS TO TREAT HIV INFECTION AND AIDS | US GOV HEALTH & HUMAN SERV (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1463741-A2 | COMPOUNDS TO TREAT HIV INFECTION AND AIDS | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003049695-A2 | COMPOUNDS TO TREAT HIV INFECTION AND AIDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2003-06-19 | — | — | WO | disclosed |
| CN-1037176-C | Benzenealkanoic acids for cardiovascular diseases | PFIZER RES & DEV (IE) | 1998-01-28 | — | — | CN | disclosed |
| CN-1087080-A | The phenyl alkane acids class of treatment cardiovascular disorder | PFIZER RES & DEV (IE) | 1994-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAPT 2196/4885SMN1; SMN2 3834/4885L3MBTL1 1503/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | MAPT 2196/4885SMN1; SMN2 3834/4885L3MBTL1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.